Market View

he U.S. market remains is in an Uptrend Under Pressure. The S&P 500 and Nasdaq pulled back to their respective 50-DMA in volatile action this week. Support below this major moving average is ~3,700 on the S&P 500, which is near the January 29 low and the rising 100-DMA. Support below the 50-DMA for the Nasdaq is between 12,900 and 13,000, an area that held twice in January. The distribution day count stands at five each with two expiring on the S&P 500 and one on the Nasdaq next week.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq pulled back slightly this week but

held above support at the 10-DMA (S&P 500: 3,905) and 21-DMA (Nasdaq:13,720), respectively. The distribu-
tion day count stands at four and three days, respectively, with one day expiring on the S&P 500 next week.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq built on last week’s strong gains,
moving further into all-time highs this week. Near-term support remains the rising 10- and 21-DMA (S&P 500:
3,848; Nasdaq: 13,610). The distribution day count remains relatively low at five and two, respectively, with one
day expiring on the S&P 500 next week.

Market View

The U.S. market is back in a Confirmed Uptrend. The S&P 500 and Nasdaq rebounded strongly from moving
average support this week, pushing all the way back to new all-time highs. Near-term support is again the rising
10- and 21-DMA (S&P 3,804; Nasdaq: 13,358). Both indices avoided distribution, keeping the count at six and
three, respectively, with one day expiring on the S&P 500 and two on the Nasdaq next week.

Dr Lal Pathlabs

Key points from this report:

 

  • Buy Dr Lal Pathlabs. The stock is breaking out of a stage-one flat base in heavy volume.
  • Better-than-expected Q3 FY21 results. Revenue and net income beat consensus by 12% and 30%, respectively, driven by a strong recovery in its core business and double-digit volume growth. The core business has fully recovered, increasing 8% y/y in the quarter.
  • Geographical expansion. The company announced the opening of two new reference labs in the West and South regions of India. These labs will be more technologically advanced and less capex heavy.
  • Better positioning among peers. Dr Lal Pathlabs is the largest branded diagnostic chain in India in terms of samples processed. In the first nine months of FY21, the company processed 34.6M (-5% y/y) samples, compared with Metropolis’s 12.6M and 9.2M for SRL Diagnostic in H1 FY21.
  • Next catalyst. The company will announce Q4 FY21 results in April. For FY21, consensus expects revenue and EPS growth of 16% and 24%, y/y, respectively. For FY22, consensus expects revenue and EPS growth of 15% and 20% y/y, respectively.